DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma

NCT06194695 · clinicaltrials.gov ↗

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Cholangiocarcinoma Non-resectable

Interventions

PROCEDURE: drug eluting beads-transcatheter arterial chemoembolization
DRUG: envatinib plus anti-PD(L)1

Sponsor

Ze-yang Ding, MD

Collaborators

[object Object]
[object Object]